Guard Therapeutics International AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GUARD.ST research report →
Companyguardtherapeutics.com
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019.
- CEO
- Tobias Larsson Agervald
- IPO
- 2013
- Employees
- 12
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $25.05M
- P/E
- -0.31
- P/S
- 0.00
- P/B
- 0.69
- EV/EBITDA
- 0.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -151.94%
- ROIC
- -209.71%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-108,851,000 · -13.31%
- EPS
- $-6.04 · 29.93%
- Op Income
- $-107,736,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $27.00
- 52W Low
- $0.88
- 50D MA
- $1.28
- 200D MA
- $7.02
- Beta
- 0.50
- Avg Volume
- 35.42K
Get TickerSpark's AI analysis on GUARD.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GUARD.ST Coverage
We haven't published any research on GUARD.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GUARD.ST Report →